Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.
作者： Julia Hornig , Alistair McGregor
DOI: 10.1517/17460441.2014.922538
关键词:
摘要: Introduction: Although a number of antiviral agents are licensed for treatment some human herpesvirus (HHV) infections, effective therapy is not available all HHVs. Additional complications associated with approved drugs, such as toxicity and side effects, rise in drug-resistant strains driving force new drug development. Success HHV vaccine development limited only vaccines against varicella-zoster virus currently use the clinic. In vitro, vivo silico high-throughput (HTP) approaches innovative microfluidic systems will provide novel technologies to efficiently identify evaluate targets antiherpetic compounds. Coupled HTP strategies manipulation viral genomes, these greatly accelerate future antivirals well candidate intervention strategies.Areas covered: The authors brief overview family diseases. Further, au...
informahealthcare.com
researchgate.net 参考文章(170)
Lihong Chen, Jian Liu, Wei Wang, Jianghui Ye, Lanling Wen, Qinjian Zhao, Hua Zhu, Tong Cheng, Ningshao Xia, Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. Journal of Virological Methods. ,vol. 200, pp. 10- 14 ,(2014) , 10.1016/J.JVIROMET.2014.01.014
Ali Azizi, Mei Tang, Lucy Gisonni-Lex, Laurent Mallet, Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach BMC Microbiology. ,vol. 13, pp. 284- 284 ,(2013) , 10.1186/1471-2180-13-284
Sebastian J. Maerkl, Integration column: Microfluidic high-throughput screening Integrative Biology. ,vol. 1, pp. 19- 29 ,(2009) , 10.1039/B819762H
Christian Gilbert, Julie Bestman-Smith, Guy Boivin, Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resistance Updates. ,vol. 5, pp. 88- 114 ,(2002) , 10.1016/S1368-7646(02)00021-3
Jennifer Beam Dowd, Tia Palermo, Jennifer Brite, Thomas W. McDade, Allison Aiello, Seroprevalence of Epstein-Barr Virus Infection in U.S. Children Ages 6-19, 2003-2010 PLoS ONE. ,vol. 8, pp. e64921- ,(2013) , 10.1371/JOURNAL.PONE.0064921
P. W. Krug, R. F. Schinazi, J. K. Hilliard, Inhibition of B Virus (Macacine herpesvirus 1) by Conventional and Experimental Antiviral Compounds Antimicrobial Agents and Chemotherapy. ,vol. 54, pp. 452- 459 ,(2010) , 10.1128/AAC.01435-08
M.A Epstein, B.G Achong, Y.M Barr, VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. The Lancet. ,vol. 283, pp. 702- 703 ,(1964) , 10.1016/S0140-6736(64)91524-7
Yoshiko Fukui, Keiko Shindoh, Yumiko Yamamoto, Shin Koyano, Isao Kosugi, Toyofumi Yamaguchi, Ichiro Kurane, Naoki Inoue, Establishment of a Cell-Based Assay for Screening of Compounds Inhibiting Very Early Events in the Cytomegalovirus Replication Cycle and Characterization of a Compound Identified Using the Assay Antimicrobial Agents and Chemotherapy. ,vol. 52, pp. 2420- 2427 ,(2008) , 10.1128/AAC.00134-08
Natalia Cheshenko, Marla J. Keller, Veronica MasCasullo, Gary A. Jarvis, Hui Cheng, Minnie John, Jin-Hua Li, Kathleen Hogarty, Robert A. Anderson, Donald P. Waller, Lourens J. D. Zaneveld, Albert T. Profy, Mary E. Klotman, Betsy C. Herold, Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread Antimicrobial Agents and Chemotherapy. ,vol. 48, pp. 2025- 2036 ,(2004) , 10.1128/AAC.48.6.2025-2036.2004
K. Abel, J. Martinez, Y. Yue, S. F. Lacey, Z. Wang, L. Strelow, A. Dasgupta, Z. Li, K. A. Schmidt, K. L. Oxford, B. Assaf, J. A. Longmate, D. J. Diamond, P. A. Barry, Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques Journal of Virology. ,vol. 85, pp. 2878- 2890 ,(2011) , 10.1128/JVI.00883-10